As p53 mutations in tumors tend to recur more frequently and develop distant metastases within five years in 50% of cases, it is of great interest to determine the presence of potential targets for future targeted therapies, which be of some benefit in the treatment of these varieties of endometrial cancer, whether or not they are targeted in conventional radio/chemotherapy [9]. This evidence concerns the gene TP53 and endometrial cancer.